Tempest Therapeutics Inc

NASDAQ TPST

Data sourced from

and

Daily

Download Data

Tempest Therapeutics Inc Share Price on June 03, 2024: USD 3.25

Tempest Therapeutics Inc Share Price is USD 3.25 on June 03, 2024, a 122.60% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Tempest Therapeutics Inc 52-week high Share Price is USD 9.77 on October 11, 2023, which is 200.62% above the current Share Price.
Tempest Therapeutics Inc 52-week low Share Price is USD 0.23 on October 09, 2023, which is -92.92% below the current Share Price.
Tempest Therapeutics Inc average Share Price for the last 52 weeks is USD 2.78.

NASDAQ: TPST

Tempest Therapeutics Inc

CEO	Mr. Stephen R. Brady J.D., LLM
IPO Date	Nov. 12, 2012
Location	United States
Headquarters	7000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	17
Sector	Healthcare
Industry	Biotechnology

Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Key trends